Kyverna Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Kyverna Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.65M.
- Kyverna Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $243.00K, a 8000.00% increase year-over-year.
- Kyverna Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.65M, a 1734.44% increase year-over-year.
- Kyverna Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $3.00K, a 95.31% decline year-over-year.
- Kyverna Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.99M, a 667.18% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $259.00K, a 59.84% decline from fiscal 2023.
- Kyverna Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $645.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.65M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $243.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $1.99M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $1.65M 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $3.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $259.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $90.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $73.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $64.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $645.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $310.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $36.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $24.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |